CLAIM CARD
The evidence base for PCSK9 inhibition and immune-inflammatory outcomes is anchored by a double-blind, placebo-controlled, multicenter pilot trial. This mechanistic human study was designed as a proof-of-concept intervention during the hyperinflammatory phase of SARS-CoV-2 infection. The intervention under investigation was a PCSK9 inhibitor administered during the acute inflammatory stage. This trial represents the most direct clinical evidence linking PCSK9 modulation to immune pathways in a human disease context.
Evidence grade: exploratory
Contradiction status: none
Publication: 4753c82f-24d3-490c-8a23-6cc8d4194c24
Provenance: Derivation Web chain
Citation Support
source_1Ma 2025source_2Schwartz 2021source_3Lehrke 2024source_4Imran 2023source_5Faraidy 2023